Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunoglobulin E (IgE). Collectively, these types of diseases contribute to substantial morbidity and loss of productivity in affected individuals. Although existing treatments—including nasal and inhaled corticosteroids, bronchodilators, leukotriene antagonists, decongestants, mast cell stabilizers, allergen immunotherapies, and biologics—address the needs of many patients, these therapies prove inadequate for some patients. Asthma therapies such as Roche / Novartis’s well-known anti-IgE agent Xolair are being tested for these disorders. Novel therapies with distinct modes of action and/or targets are also in clinical development to expand treatment options for inadequately controlled patients. The availability of these emerging therapies has the potential to significantly improve patient health outcomes and quality of life.
- What is the landscape for emerging therapies targeting allergic respiratory disorders? What are the key features in ongoing clinical trials?
- What are interviewed KOLs’ opinions about therapies in development for allergic respiratory disorders?
- How do experts in the field believe these agents compare with existing therapies?
- What do thought leaders consider the prevailing areas of unmet need and opportunity in the treatment of various allergic respiratory disorders?
Geographies– United States and EU5
Primary Research– Interviews with ten allergic respiratory disorder experts (allergists, pulmonologists, otolaryngologists) from the United States and Europe
Key Insights Provided
- Pipeline review: therapies for allergic rhinitis, chronic rhinosinusitis, and nasal polyps.
- KOLs’ awareness and perceptions of key therapies targeting allergic respiratory disorders.
- Expectations for emerging therapies versus existing treatments for allergic respiratory disorders.
DRG’s Special Topics reports assess key trends in dynamic disease areas. This report on allergic respiratory disorders will help developers gain needed insight into the clinical development of therapies that could shape the future of this market.
- Allergic Rhinitis - Special Topics - Allergic Respiratory Disorders | Special Topics | US
Author(s): Shubhendu Ghosh, PhD
Shubhendu Ghosh, Ph.D., is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma.
Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his Ph.D. in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.